胞赤芽細胞の腫瘍誘発生成は,腫瘍の進行を促進する
PubMedで要約を見る
まとめ
この要約は機械生成です。研究 者 たち は,がん の 進行 を 促進 する 新しい 腫瘍 誘導 性 の エリトロブラスト 型 細胞 (Ter 細胞) を 発見 し まし た. これらの細胞は,肝細胞癌 (HCC) 患者における予後不良に関連した要因であるアルテミンを分泌する.
科学分野
- 腫瘍学
- 血液学
- 細胞生物学
背景
- 癌は様々な細胞によって 影響を受ける全身疾患です
- 癌の拡散における遠隔臓器における非白血球群の役割は十分に理解されていません.
研究 の 目的
- 癌の進行に寄与する新しい非白血球集団を特定し,特徴づけること.
- これらの細胞が腫瘍の広がりを促進するメカニズムを調査する.
主な方法
- フローサイトメトリー (Ter-119+,CD45-,CD71+) を用いた腫瘍誘導性細胞 (Ter細胞) のフェノタイプの特徴づけ.
- 腫瘍を持つ宿主におけるTer細胞濃縮と,その分泌因子の分析.
- アルテミンの阻害とアルテミンの欠乏に関する in vivo 実験
- ヒト肝細胞癌 (HCC) のサンプルにおけるTer細胞とアルテミンの検出
主要な成果
- メガカリオサイト - エリトロイドの原始細胞から発生した腫瘍誘導性赤血球細胞 (Ter細胞) を特定した.
- 臓に濃縮されたTer細胞は神経栄養因子アルテミンを分泌し,腫瘍の進行を促進します.
- 変換成長因子β (TGF-β) とSmad3シグナリングは,Ter細胞生成に不可欠である.
- Ter細胞由来アルテミンは,体内でHCCの増殖を阻害した.
- アルテミンの欠乏は 腫瘍を助長するTer細胞の効果を 打ち消しました
- 脊髄アルテミン陽性Ter細胞はヒトHCC患者で発見され,血清アルテミンの値上昇は予後不良と相関していました.
結論
- 癌の進行に寄与する新しい非白血球集団を表します.
- Ter細胞によって分泌されるアルテミンは,肝細胞癌 (HCC) の成長と全身的拡散に重要な役割を果たします.
- アルテミンとTer細胞は,HCCにおける予後バイオマーカーと治療標的として潜在的です.
関連する概念動画
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences. The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...

